Jan 14, 2020 / 10:30PM GMT
Christopher Thomas Schott - JP Morgan Chase & Co, Research Division - Senior Analyst
Good afternoon. I'm Chris Schott from JPMorgan. And it's my pleasure to be hosting this session with Eli Lilly today. From Lilly, we have the company's Chairman and CEO, Dave Ricks.
Dave, thanks for joining us for the fireside again this year. It was obviously a very busy year for Lilly, again, in 2019. Seems like 2020 is setting up to be an important one for the company. Before we dig into this -- the specific topics on the fireside, do you want to make some opening remarks, and we'll...
David A. Ricks - Eli Lilly and Company - Chairman, CEO & President
Yes, absolutely. Thanks for having us again, and I want to thank my team here in the room. We had a strong year last year, and it's due to their hard work.
Maybe just to frame before we get into this, we just had our guidance call on December '19 for 2020. And it ends a period of remarkable progress for the company. As we exited a series of patent expiries in 2015, we set out a series of goals and
Eli Lilly and Co at JPMorgan Healthcare Conference Transcript
Jan 15, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers